# Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

> **NCT03607188** · PHASE1 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 17 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Alkotinib

## Key facts

- **NCT ID:** NCT03607188
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-18
- **Primary completion:** 2022-10-17
- **Final completion:** 2022-10-17
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03607188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03607188, "Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03607188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*